ClinicalTrials.gg
TerminatedNCT05288543Updated Dec 22, 2025

A Study of Orally Administered IPG7236 in Healthy Adult Participants

A Phase 1 interventional study of IPG7236- Single ascending dose and IPG7236- Multiple ascending dose in Atopic Dermatitis, sponsored by Nanjing Immunophage Biotech Co., Ltd. Terminated at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Dermatitis, Atopic with a site in Australia — 12 open to participants now, 27 under way, 7 of them phase 3. Dermatitis, Atopic · Australia.

Enrollment
87th of 105
63 · median 226
Started
2022
with 8 others
Phase 1
19 of 110
8 open now
Registered
74th of 110
by date

Among the 110 studies in Dermatitis, Atopic with a site in Australia, this one is the 87th largest by enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2022, is one of 19 in phase 1, and was the 74th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

12 of the 110 studies in Dermatitis, Atopic with a site in Australia are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Dermatitis, Atopic with a site in Australia, or all of them as a file.
02

Study summary

The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect of orally administered IPG7236 in healthy adult participants.

Read the detailed description

The study consists of two parts

Part A (Single ascending dose): There are total 8 Single Ascending Dose cohorts.

Dose levels are as follows Cohort 1: 25 mg of IPG7236 or placebo as per the randomization code, Cohort 2: 50 mg of IPG7236 or placebo as per the randomization code Cohort 3: 100 mg of IPG7236 or placebo as per the randomization code Cohort 4: 200 mg of IPG7236 or placebo as per the randomization code Cohort 5: 300 mg of IPG7236 or placebo as per the randomization code Cohort 6: 400 mg of IPG7236 or placebo as per the randomization code Cohort 7: 500 mg of IPG7236 or placebo as per the randomization code Cohort 8: 600 mg of IPG7236 or placebo as per the randomization code In Cohort 1 total of 6 subjects enrolled. The 4 subjects will receive IPG7236 and 2 subjects will receive the placebo as per the randomization code.

In Cohort 2 to Cohort 8, 6 subjects will receive IPG7236 and 2 subjects will receive the placebo as per the randomization code.

Part B (Multiple ascending dose): There are total 3 Multiple ascending dose cohorts.

Dose levels are as follows Cohort 1: 100 mg of IPG7236 or placebo as per the randomization code Cohort 2: 300 mg of IPG7236 or placebo as per the randomization code Cohort 3: 500 mg of IPG7236 or placebo as per the randomization code Total of 8 subjects per cohort, 6 subjects will receive IPG7236 and 2 subjects will receive placebo per the randomization code The Multiple Ascending Dose phase of Cohort 1, Cohort 2 and Cohort 3 will commence based on the safety and tolerability data obtained from Single Ascending Dose phase of Cohort 4, Cohort 6 and Cohort 8.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or female participants between 18 and 55 years of age (inclusive).
  2. Body weight between 45 and 100 kg (inclusive) and (BMI) within 18\~32 kg/m2 (inclusive).

    Health status

  3. In good health as determined by screening tests. Good health is defined as having no abnormalities identified by a detailed medical history, full physical examination (including measurement of blood pressure and pulse rate), 12-lead Electrocardiograph (), and clinical laboratory tests.

    • Vital signs (measured after resting for 5 minutes semi-supine position) within a normal range of the clinical site,, or outside the normal range and not considered clinically significant by the Investigator.
    • Standard 12-lead Electrocardiograph (ECG) parameters (recorded after resting for 5 minutes in semi-supine position) in the following ranges; (Fridericia algorithm recommended) ≤ 450 ms for males and 470 ms for females, and normal ECG tracing, or abnormal ECG tracing not considered clinically relevant by the Investigator.
    • Laboratory parameters demonstrating no clinically significant abnormalities, as determined by the Investigator. Total outside the normal range may be acceptable if total bilirubin does not exceed 1.5x with normal conjugated bilirubin (with the exception of a patient with documented Gilbert syndrome).
  4. A negative result on urine drug screen and a repeat negative result on Day -1 (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates).
  5. Female participants must not be pregnant or breastfeeding and must use an effective method with the exception of participants who have undergone sterilization more than 3 months prior to screening or who are .

    A woman of (WOCBP) must undergo pregnancy testing prior to the first dose of the study drug. The participant must be excluded from the study if the serum pregnancy test is positive.

    A postmenopausal state is defined as 12 months of amenorrhea without an alternative medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed by follicle stimulating hormone (FSH) measurement (> 40 IU/L or mIU/mL).

    Females on HRT (Hormonal Replacement therapy), where menopausal status is indeterminate, will be required to use a non-estrogen hormonal contraceptive method if participants wish to continue their HRT during the study. Participants must otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to enrollment in the study.

  6. Provide written prior to undertaking any study-related procedures.
  7. Must not be under any administrative or legal supervision or under institutionalization as per a regulatory or juridical order.

Exclusion criteria

Exclusion Criteria:

  1. Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, musculoskeletal, rheumatological, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
  2. Frequent severe headaches and/or migraines, recurrent nausea and/or vomiting (defined as vomiting more than twice a month).
  3. Made a blood or plasma donation of ≥500 ml within 1 month prior to the first dose.
  4. Demonstrated clinically significant (required intervention, e.g., emergency room visit, epinephrine administration) allergic reactions, which in the opinion of the Investigator, would interfere with the volunteer's ability to participate in the trial.
  5. Known to any component of the IMP formulation.
  6. History or presence of drug or alcohol abuse (defined as alcohol consumption of more than 2 units per day on a regular basis).
  7. Regular smoking (defined as more than 5 cigarettes or equivalent per week), or unable to stop smoking during the study. Occasional smokers may be enrolled but need to abstain during admission to the site
  8. Excessive consumption of beverages containing xanthine bases (defined as more than 4 glasses per day).
  9. Any medication, including St John's Wort, within 14 days prior to administration of the first dose or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal , menopausal hormone replacement therapy, or occasional paracetamol at doses up to 2g/day.
  10. Any consumption of grapefruit or products containing grapefruit within 5 days prior to the first dose administration.
  11. Any vaccination in the 2 weeks prior to administration of the first dose (Covid19 vaccination included, and planned COVID19 vaccinations, including booster shots, during the study or for 2 weeks after the last dose of the study drug)
  12. Any participant who, in the judgment of the Investigator, is likely to be non-compliant during the study, or to be unable to cooperate due to language problems or poor mental development.
  13. Any participant who enrolled in or participated in any other clinical study involving an medicinal product, or in any other type of medical research within 1 month or within 5 times the elimination half-life prior to administration of the first dose.
  14. Any participant who cannot be contacted in the case of an emergency.
  15. Any participant who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, or other staff thereof directly involved in conducting the study or any person dependent on (employees or immediate family members) the study site, the Investigator or the Sponsor.

    Biological status

  16. Positive result on any of the following tests: surface antigen (HbsAg), hepatitis B core antibodies (HbcAb), anti- virus antibodies (anti-HCV), anti- 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).
  17. Positive alcohol test at D-1.
  18. Any participant in whom venous blood collection is difficult.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose Phase

    Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (25 mg), Cohort 2 (50 mg), Cohort 3 (100 mg), Cohort 4 (200 mg), Cohort 5 (300 mg), Cohort 6 (400 mg), Cohort 7 (500 mg) and Cohort 8 (600 mg)

    Drug: IPG7236- Single ascending dose

  • Experimental
    Multiple Ascending Dose Phase

    Drug: IPG7236 Dosage form: Tablet Route of Administration: Oral Dose level: Cohort 1 (100 mg), Cohort 2 (300 mg) and Cohort 3 (500 mg)

    Drug: IPG7236- Multiple ascending dose

  • Placebo comparator
    Part A (Placebo)

    Placebo tablets identical to IPG7236 tablets Dosage form: Tablet Route of Administration: Oral

    Other: Placebo (Part A)

Interventions

  • DrugIPG7236- Single ascending dose

    Drug pages: IPG-7236 · CCR8 Inhibitor IPG7236

    Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state

  • DrugIPG7236- Multiple ascending dose

    Drug pages: IPG-7236 · CCR8 Inhibitor IPG7236

    Subjects will receive IPG7236 tablets orally once daily for 10 days from Day1 to Day 10 in a fasted state

  • OtherPlacebo (Part A)

    Subjects will receive IPG7236 tablets orally once on Day 1 (Part A) or once daily for 10 days from Day1 to Day 10 (Part B) in a fasted state

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of IPG7236 after ascending single oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5

    Time frame: Up to 36 days

  2. To assess the safety and tolerability of IPG7236 after ascending multiple oral doses through adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events v5

    Time frame: Up to 45 days

Secondary outcomes

  1. To assess the pharmacokinetic (PK) parameters of IPG7236 after ascending single oral doses

    Plasma PK parameters: Cmax (maximum plasma concentration)

    Time frame: Up to 36 days

  2. To assess the pharmacokinetic (PK) parameters of IPG7236 after ascending single oral doses

    Plasma PK parameters: Tmax (time to Cmax)

    Time frame: Up to 36 days

  3. To assess the pharmacokinetic (PK) parameters of IPG7236 after ascending multiple oral doses

    Plasma PK parameters: Css,max (maximum plasma concentration at steady state)

    Time frame: Up to 45 days

  4. To assess the pharmacokinetic (PK) parameters of IPG7236 after ascending multiple oral doses

    Plasma PK parameters: CTss,max (time to maximum plasma concentration at steady state)

    Time frame: Up to 45 days

  5. To evaluate the effect of food on the PK of IPG7236

    Pharmacokinetics parameters using Cmax (maximum plasma concentration)

    Time frame: Up to 45 days

07

Study locations

1 site
  • Scientia Clinical Research Ltd
    Randwick, New South Wales 2031, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Mar 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2022
First posted
Mar 21, 2022
StartActual
Apr 7, 2022
Primary completionActual
Mar 31, 2023
CompletionActual
Nov 26, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05288543
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Mar 21, 2022
Start date
Apr 7, 2022
Primary completion
Mar 31, 2023
Completion
Nov 26, 2025
Last update
Dec 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: IPG-7236 · CCR8 Inhibitor IPG7236

Start the discussion